| Schedule of Earnings Per Share |
The following table presents the calculation of basic and diluted net income (loss) per share for Class A and Class B common stock. No shares of Class C common stock were issued and outstanding during the periods presented. | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | 2026 | | 2025 | | Class A
Common | | Class B
Common | | Class A
Common | | Class B
Common | | (In thousands, except per share data) | | Numerator: | | | | | | | | | Income (loss) from continuing operations | $ | (2,403) | | | $ | (33) | | | $ | 11,807 | | | $ | 167 | | | Less: Accretion of Series A Preferred Stock to redemption value | (5,061) | | | (70) | | | (4,494) | | | (64) | | | Net income (loss) attributable to Blend Labs, Inc. common stockholders from continuing operations | (7,464) | | | (103) | | | 7,313 | | | 103 | | | Undistributed earnings attributable to participating securities | — | | | — | | | (1,104) | | | (15) | | | Net income (loss) attributable to Blend Labs, Inc. common stockholders from continuing operations | (7,464) | | | (103) | | | 6,209 | | | 88 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Net income attributable to Blend Labs, Inc. from discontinued operations | 483 | | | 7 | | | 120 | | | 2 | | | Undistributed earnings attributable to participating securities | — | | | — | | | (18) | | | — | | | Net income attributable to Blend Labs, Inc. common stockholders from discontinued operations | 483 | | | 7 | | | 102 | | | 2 | | | | | | | | | | | Net income (loss) attributable to Blend Labs, Inc. common stockholders | $ | (6,981) | | | $ | (96) | | | $ | 6,311 | | | $ | 90 | | | | | | | | | | | Denominator: | | | | | | | | | Weighted average common stock outstanding, basic | 234,075 | | | 3,256 | | | 256,004 | | | 3,627 | | | Effect of dilutive securities | — | | | — | | | 8,961 | | | 127 | | | Weighted average diluted securities | 234,075 | | | 3,256 | | | 264,965 | | | 3,754 | | | | | | | | | | | Net income (loss) per share from continuing operations | | | | | | | | | Basic | $ | (0.03) | | | $ | (0.03) | | | $ | 0.02 | | | $ | 0.02 | | | Diluted | $ | (0.03) | | | $ | (0.03) | | | $ | 0.02 | | | $ | 0.02 | | | Net income (loss) per share from discontinued operations | | | | | | | | | Basic and diluted | $ | 0.00 | | | $ | 0.00 | | | $ | 0.00 | | | $ | 0.00 | | | Net income (loss) per share attributable to Blend Labs, Inc.: | | | | | | | | | Basic | $ | (0.03) | | | $ | (0.03) | | | $ | 0.02 | | | $ | 0.02 | | | Diluted | $ | (0.03) | | | $ | (0.03) | | | $ | 0.02 | | | $ | 0.02 | |
| | | | | | | | | | | | | | | | | | | | | | | | | Nine Months Ended September 30, | | 2026 | | 2025 | | Class A
Common | | Class B
Common | | Class A
Common | | Class B
Common | | (In thousands, except per share data) | | Numerator: | | | | | | | | | Income (loss) from continuing operations | $ | (9,584) | | | $ | (129) | | | $ | 1,211 | | | $ | 18 | | | Less: Accretion of Series A Preferred Stock to redemption value | (14,592) | | | (197) | | | (12,949) | | | (187) | | | Net loss attributable to Blend Labs, Inc. common stockholders from continuing operations | (24,176) | | | (326) | | | (11,738) | | | (169) | | | | | | | | | | | Net loss from discontinued operations | (1,741) | | | (24) | | | (5,598) | | | (81) | | Less: Accretion of RNCI to redemption value from discontinued operations | — | | | — | | | (1,236) | | | (18) | | | Less: Net loss attributable to noncontrolling interest included in discontinued operations | — | | | — | | | 179 | | | 3 | | | Net loss attributable to Blend Labs, Inc. common stockholders from discontinued operations | (1,741) | | | (24) | | | (6,655) | | | (96) | | | | | | | | | | | Net loss attributable to Blend Labs, Inc. common stockholders | $ | (25,917) | | | $ | (350) | | | $ | (18,393) | | | $ | (265) | | | | | | | | | | | Denominator: | | | | | | | | | Weighted average common stock outstanding, basic and diluted | 240,967 | | | 3,256 | | | 255,528 | | | 3,700 | | | | | | | | | | | | | | | | | | | | | | | | | | | Net loss per share from continuing operations | | | | | | | | | Basic and diluted | $ | (0.10) | | | $ | (0.10) | | | $ | (0.04) | | | $ | (0.04) | | | Net loss per share from discontinued operations | | | | | | | | | Basic and diluted | $ | (0.01) | | | $ | (0.01) | | | $ | (0.03) | | | $ | (0.03) | | | Net loss per share attributable to Blend Labs, Inc.: | | | | | | | | | Basic and diluted | $ | (0.11) | | | $ | (0.11) | | | $ | (0.07) | | | $ | (0.07) | |
|
| Schedule of Antidilutive Securities |
The following potential shares of common stock were excluded from the computation of diluted net earnings per share for the three and nine months ended September 30, 2026 and the nine months ended September 30, 2025 because including them would have been anti-dilutive as the Company has reported net loss for each of the periods: | | | | | | | | | | | | | | | | | As of September 30, | | | | 2026 | | 2025 | | | | | | (In thousands) | | | | | | Outstanding stock options | 14,418 | | | 15,403 | | | | | | | | | | | | | | | Non-plan Co-Founder and Head of Blend options | 20,194 | | | 20,194 | | | | | | | Unvested restricted stock units | 11,812 | | | 11,543 | | | | | | Unvested performance stock awards(1) | 7,377 | | | 8,235 | | | | | | | Series G Warrant | 598 | | | 598 | | | | | | | Haveli Warrant | — | | | 11,111 | | | | | | | Series A redeemable convertible preferred stock | 46,154 | | | 46,154 | | | | | | | Total anti-dilutive securities | 100,553 | | | 113,238 | | | | | |
____________ (1) Performance conditions for awards with market vesting conditions were not satisfied for the unvested performance stock awards as of September 30, 2026.
|